IS4557A - Notkun fumagillóls og afleiða þess við framleiðslu lyfja gegn þarmasýkingu - Google Patents

Notkun fumagillóls og afleiða þess við framleiðslu lyfja gegn þarmasýkingu

Info

Publication number
IS4557A
IS4557A IS4557A IS4557A IS4557A IS 4557 A IS4557 A IS 4557A IS 4557 A IS4557 A IS 4557A IS 4557 A IS4557 A IS 4557A IS 4557 A IS4557 A IS 4557A
Authority
IS
Iceland
Prior art keywords
fumagillol
derivatives
manufacture
inflammatory drugs
inflammatory
Prior art date
Application number
IS4557A
Other languages
English (en)
Other versions
IS2048B (is
Inventor
Molina Jean-Michel
Derouin Francis
Original Assignee
Sanofi-Aventis
Assistance Publique-Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis, Assistance Publique-Hopitaux De Paris filed Critical Sanofi-Aventis
Publication of IS4557A publication Critical patent/IS4557A/is
Publication of IS2048B publication Critical patent/IS2048B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
IS4557A 1995-03-27 1997-09-11 Notkun fumagillóls og afleiða þess við framleiðslu lyfja gegn þarmasýkingu IS2048B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
IS4557A true IS4557A (is) 1997-09-11
IS2048B IS2048B (is) 2005-09-15

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4557A IS2048B (is) 1995-03-27 1997-09-11 Notkun fumagillóls og afleiða þess við framleiðslu lyfja gegn þarmasýkingu

Country Status (25)

Country Link
US (1) US5900431A (is)
EP (1) EP0817626B1 (is)
JP (1) JP3260378B2 (is)
KR (1) KR100286920B1 (is)
CN (1) CN1072485C (is)
AP (1) AP646A (is)
AT (1) ATE172641T1 (is)
AU (1) AU706161B2 (is)
CA (1) CA2216623C (is)
CZ (1) CZ286821B6 (is)
DE (1) DE69600879T2 (is)
DK (1) DK0817626T3 (is)
EA (1) EA000150B1 (is)
ES (1) ES2128846T3 (is)
FR (1) FR06C0014I2 (is)
HU (1) HU224028B1 (is)
IS (1) IS2048B (is)
NO (1) NO315968B1 (is)
NZ (1) NZ304906A (is)
OA (1) OA10515A (is)
PL (1) PL183378B1 (is)
SK (1) SK283883B6 (is)
TR (1) TR199701048T1 (is)
UA (1) UA41446C2 (is)
WO (1) WO1996030010A2 (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
ATE361757T1 (de) 1999-02-26 2007-06-15 Sanofi Aventis Stabile fumagillin-formulierung
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
EP2217283A2 (en) * 2007-11-28 2010-08-18 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
NZ590732A (en) * 2008-07-18 2012-09-28 Zafgen Inc Methods of treating an overweight or obese subject using fumagillin
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
MX343135B (es) 2010-01-08 2016-10-25 Zafgen Corp * Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
MX2013005208A (es) 2010-11-09 2013-08-01 Zafgen Inc Sólidos cristalinos de un inhibidor de metionina aminopeptidasa 2 y métodos para obtener y usar los mismos.
EP2646016B1 (en) 2010-11-29 2017-05-17 Zafgen, Inc. Treatment if obesity using non-daily administration of 6-0-(4-dimethylaminoethoxy)cinnamoyl fumagillol
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
AU2012225531B2 (en) 2011-03-08 2017-03-30 Zafgen, Inc Oxaspiro (2.5) octane derivatives and analogs
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
CA2835195A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
KR20140112565A (ko) 2012-01-18 2014-09-23 자프겐 인크. 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
AU2013259760A1 (en) 2012-05-07 2014-11-20 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol and methods of making and using same
AU2013259617A1 (en) 2012-05-08 2014-11-27 Zafgen, Inc. Treating hypothalamic obesity with MetAP2 inhibitors
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
SG11201503521QA (en) 2012-11-05 2015-06-29 Zafgen Inc Methods of treating liver diseases
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
CA2904353A1 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
WO1992002240A2 (en) * 1990-07-27 1992-02-20 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
KR100286920B1 (ko) 2001-04-16
IS2048B (is) 2005-09-15
EA000150B1 (ru) 1998-10-29
CZ286821B6 (en) 2000-07-12
WO1996030010A2 (fr) 1996-10-03
CN1179715A (zh) 1998-04-22
CZ304997A3 (en) 1997-12-17
NO315968B1 (no) 2003-11-24
EP0817626A2 (fr) 1998-01-14
OA10515A (fr) 2002-04-24
CA2216623C (en) 2005-05-31
TR199701048T1 (xx) 1998-01-21
DE69600879D1 (de) 1998-12-03
US5900431A (en) 1999-05-04
UA41446C2 (uk) 2001-09-17
CN1072485C (zh) 2001-10-10
HU224028B1 (hu) 2005-05-30
MX9707150A (es) 1998-07-31
WO1996030010A3 (fr) 1996-11-28
SK130797A3 (en) 1998-03-04
DK0817626T3 (da) 1999-07-12
FR06C0014I1 (is) 2006-11-17
NO974466L (no) 1997-09-26
JP3260378B2 (ja) 2002-02-25
NO974466D0 (no) 1997-09-26
ATE172641T1 (de) 1998-11-15
AU706161B2 (en) 1999-06-10
FR06C0014I2 (is) 2006-12-29
JPH11506421A (ja) 1999-06-08
AU5278696A (en) 1996-10-16
HUP9801220A2 (hu) 1999-09-28
HUP9801220A3 (en) 2001-10-29
NZ304906A (en) 1999-06-29
AP9701092A0 (en) 1997-10-31
ES2128846T3 (es) 1999-05-16
PL322470A1 (en) 1998-02-02
SK283883B6 (sk) 2004-04-06
KR19980703271A (ko) 1998-10-15
EP0817626B1 (fr) 1998-10-28
DE69600879T2 (de) 1999-06-02
EA199700267A1 (ru) 1998-04-30
PL183378B1 (pl) 2002-06-28
AP646A (en) 1998-04-27
CA2216623A1 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
IS4557A (is) Notkun fumagillóls og afleiða þess við framleiðslu lyfja gegn þarmasýkingu
FI953479A (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
NO308740B1 (no) Kinazolinderivater, anvendelse derav og farmasøytisk blanding
NO961425D0 (no) 1N-alkyl-N-arylpyrimidinaminer og derivater derav
FI961599A (fi) 1N-alkyyli-N-aryylipyrimidiiniamiineja ja niiden johdannaisia
ITMI920528A0 (it) 14-beta idrossi-10-de acetil-baccatina iii, suoi derivati, loro preparazione ed impiego terapeutico
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
NO943511L (no) Farmasöytiske preparater og anvendelse derav
DE59208263D1 (de) 3-Aryl-4-hydroxy-delta3-dihydrofuranon- und 3-Aryl-4-hydroxy-delta3-dihydrothiophenon-Derivate
BR1100824A (pt) Composto e composição farmacêutica
EE03486B1 (et) Pürasool-4-üülbensoüüli derivaadid ja nende kasutamine herbitsiididena
DE59609556D1 (de) Zahnstangengetriebe
NO20011157L (no) Benzenderivater og farmasöytisk anvendelse derav
DK0804078T3 (da) Sammensætning og anvendelse deraf
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
FI933136A0 (fi) Antiallergiska och antiinflammatoriska n-hydroxiureaderivat
ITMI942026A0 (it) Derivati della colchicina e loro impiego terapeutico
BR9509688A (pt) Composto e composição farmacêutica
NO922934D0 (no) Cykloheksan- og tetrahydropyranderivater
FI964113A (fi) Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
EE03614B1 (et) Pürasool-4-üül-bensoüüli derivaadid ja nende kasutamine herbitsiididena
IS1813B (is) Notkun á ferróseni og/eða ferrósenafleiðum
NO20000184D0 (no) Nye purinderivater og medisinsk anvendelse derav
NO982549D0 (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav
DE69117519T2 (de) 14-o-p-chlorbenzoylaconin und analgetischer/entzündungshemmender wirkstoff